J. Hurteau

发表

Adolescents and young adults with a "rare" cancer: getting past semantics to optimal care for patients with germ cell tumors.

C. Rodríguez-Galindo, A. L. Frazier, D. Gershenson, 2014, The oncologist.

Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study

P. Bartels, D. Alberts, S. Modesitt, 2019, Cancer Prevention Research.

Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.

R. Bast, A. Berchuck, R. Whitaker, 1995, Cancer research.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

Mads Thomassen, Nina Ditsch, Vijai Joseph, 2012, Breast Cancer Research.

Effects of omega-3 fatty acids on components of the transforming growth factor beta-1 pathway: implication for dietary modification and prevention in ovarian cancer.

G. Rodriguez, J. Hurteau, Arun K. Sharma, 2009, American journal of obstetrics and gynecology.

Overexpression of a stabilized mutant form of the cyclin-dependent kinase inhibitor p27(Kip1) inhibits cell growth.

M. Goebl, Qi Wang, J. Hurteau, 2002, Gynecologic oncology.

Expression and Subcellular Localization of the Cyclin-Dependent Kinase Inhibitor p27Kip1 in Epithelial Ovarian Cancer

M. Goebl, D. Heilman, R. Bigsby, 2001 .

FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.

G. Sutton, J. Hurteau, M. Randall, 1999, Gynecologic oncology.

Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients.

W. Small, L. Mell, A. Mundt, 2005, International journal of radiation oncology, biology, physics.

A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer

E. Kohn, E. Winer, W. Barry, 2015 .

Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.

G. Sutton, M. Markman, J. Hurteau, 1998, Gynecologic oncology.

DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells.

K. Nephew, A. Ahluwalia, R. Bigsby, 2001, Gynecologic oncology.

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2019 .

Germ cell tumors: Treatment consensus across all age groups through MaGIC [Malignant Germ Cell International Collaborative]

J. Hurteau, T. Febbraro, 2016, Cancer.

Ovarian Yolk Sac Tumors; Does Age Matter?

Caihong Xia, Furqan Shaikh, Brice Fresneau, 2017, International Journal of Gynecologic Cancer.

Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group.

J. Hurteau, J. Blessing, A. Manetta, 1998, Gynecologic oncology.

Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.

R. Bast, A. Berchuck, M. Conaway, 1994, American journal of obstetrics and gynecology.

Effect of carbon dioxide on human ovarian carcinoma cell growth.

J. Hurteau, W. Hurd, V. J. Smidt, 2001, American journal of obstetrics and gynecology.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012, Breast Cancer Research.

Transforming growth factor‐β differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up‐regulation of p21WAF1

G. Sutton, R. Bigsby, J. Hurteau, 1999, Cancer.

Biochemical recurrent ovarian cancer: CA 125 elevation without symptoms or clinical evidence of disease. What is the optimal management?

J. Hurteau, E. Berry, 2006 .

Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.

G. Mills, G. Casey, Y. Xu, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

The effects of Omega-3 fatty acids on growth regulation of epithelial ovarian cancer cell lines.

J. Hurteau, Arun K. Sharma, J. Espat, 2005, Gynecologic oncology.

Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor-α

G. Mills, R. Bast, A. Berchuck, 1995 .

A Phase II Trial of Pyrazoloacridine (PZA) in Squamous Carcinoma of the Cervix – A Gynecologic Oncology Group Study

J. Lucci, J. Hurteau, J. Blessing, 2001, Investigational New Drugs.

A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix

J. Lucci, J. Hurteau, J. Blessing, 2001 .

Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery

C. Kirschner, G. Rodriguez, I. Cass, 2019, International Journal of Gynecological Cancer.

Chemotherapy‐Induced Apoptosis in Epithelial Ovarian Cancers

A. Berchuck, R. Whitaker, L. Havrilesky, 1995, Obstetrics and gynecology.

Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States

P. Thaker, J. Hurteau, P. Lefebvre, 2022, Current medical research and opinion.

Omitting lymphadenectomy in patients with endometrial cancer

J. Hurteau, 2017, Cancer.

A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgery.

J. Schilder, G. Sutton, J. Hurteau, 1997, Gynecologic oncology.

Patterns and utility of routine surveillance in high grade endometrial cancer.

E. Lengyel, C. Kirschner, S. Yamada, 2015, Gynecologic oncology.

Factors Associated With Cytoreducibility Among Women With Ovarian Carcinoma

J. Hurteau, 2006 .

Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?

S. Yamada, J. Hurteau, M. Cowan, 2019, Gynecologic oncology.

Cancer of the Ovary, Uterus, and Cervix

Jubilee Brown, J. Hurteau, 2017 .

Gestational trophoblastic disease: management of hydatidiform mole.

J. Hurteau, 2003, Clinical obstetrics and gynecology.

Complete hydatidiform mole coexisting with a twin live fetus: clinical course.

J. Schilder, J. Sumners, J. Hurteau, 1997, Gynecologic oncology.

Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?

C. Rodríguez-Galindo, A. L. Frazier, D. Gershenson, 2018, Gynecologic oncology.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

E. Kohn, E. Winer, W. Barry, 2014, The Lancet. Oncology.

Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study

R. Wenham, Joan L. Walker, P. Ramirez, 2018, American journal of obstetrics and gynecology.

Location of the ureters in relation to the uterine cervix by computed tomography.

J. Hurteau, D. Ohl, W. Hurd, 2001, American journal of obstetrics and gynecology.

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

A. Godwin, R. Mannel, K. Darcy, 2011, Gynecologic oncology.

DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization.

K. Nephew, A. Ahluwalia, P. Yan, 2001, Gynecologic oncology.

VILLOGLANDULAR ADENOCARCINOMA OF THE CERVIX: A CASE REPORT

R. Bentley, G. Rodriguez, J. Hurteau, 1995, Obstetrics and gynecology.

The risk of nodal metastasis in early adenocarcinoma of the uterine cervix*

H. Michael, G. Sutton, J. Hurteau, 2003, International Journal of Gynecologic Cancer.

Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.

B. Bundy, J. Hurteau, H. Homesley, 1999, Gynecologic oncology.

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

D. Matei, A. Oza, M. Tsao, 2020, Clinical Cancer Research.

Visualization of the epigastric vessels and bladder before laparoscopic trocar placement.

J. Hurteau, W. Hurd, L. Amesse, 2003, Fertility and sterility.

Trisomy 21 associated with ovarian dysgerminoma.

G. Sutton, J. Hurteau, L. Roth, 1999, Gynecologic oncology.

Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.

M. Munsell, K. Lu, A. Bradford, 2018, Gynecologic oncology.

Ovarian cancer

E. Kohn, J. Hurteau, 2013, Cancer.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary

Jae-Weon Kim, J. Ledermann, R. Glasspool, 2014, International Journal of Gynecologic Cancer.

Transforming growth factor‐beta inhibits proliferation of human ovarian cancer cells obtained from ascites

R. Bast, A. Berchuck, R. Whitaker, 1994, Cancer.

Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta.

R. Bast, M. Stack, R. Whitaker, 2001, Gynecologic oncology.

Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells.

M. Stack, A. Berchuck, L. Thaete, 2012, American journal of obstetrics and gynecology.

Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.

John C Roeske, Neil Mehta, J. Roeske, 2005, International journal of radiation oncology, biology, physics.

Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.

P. Thaker, J. Hurteau, P. Lefebvre, 2021 .

Gynecologic cancers metastatic to the breast.

G. Sutton, J. Hurteau, D. Moore, 1998, Journal of the American College of Surgeons.

FIGO Stage IIIC Endometrial Carcinoma With Metastases Confined to Pelvic Lymph Nodes: Analysis of Treatment Outcomes, Prognostic Variables, and Failure Patterns Following Adjuvant Radiation Therapy

G. Sutton, J. Hurteau, M. Randall, 2000 .

Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells

Vadim Backman, Lusik Cherkezyan, Hariharan Subramanian, 2013, International journal of cancer.

Cervical primitive neuroectodermal tumor.

A. Tsao, A. Sandler, J. Hurteau, 2001, Gynecologic oncology.

Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.

K. Kuchta, G. Rodriguez, J. Hurteau, 2021, Gynecologic oncology.

Soluble interleukin‐2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer

G. Mills, R. Bast, A. Berchuck, 1995, Cancer.

Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients.

G. Mills, H. Simon, J. Hurteau, 1994, American journal of obstetrics and gynecology.

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (

R. Mannel, M. Brady, K. Darcy, 2010, Gynecologic oncology.

q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012 .

Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy

O. Olopade, G. Fleming, M. Kocherginsky, 2016, PloS one.

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.

D. Alberts, M. Brady, R. Young, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer

G. Rodriguez, J. Hurteau, L. Weinberg, 2010, Journal of surgical oncology.

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

Frazier, R. Huddart, T. Powles, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The biology of ovarian cancer

R. Bast, A. Berchuck, G. Rodriguez, 1993, Current opinion in oncology.

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study.

W. Creasman, J. Hurteau, J. Blessing, 2001, Gynecologic oncology.

Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer

C. Kirschner, S. Yamada, J. Fehniger, 2017, International Journal of Gynecologic Cancer.

Cardiac metastasis from poorly differentiated carcinoma of the cervix: a case report.

E. Miller, G. Rodriguez, J. Hurteau, 2010, The Journal of reproductive medicine.

Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer

Jinlin Song, P. Thaker, J. Hurteau, 2023, American journal of clinical oncology.

The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.

C. Kirschner, G. Rodriguez, J. Hurteau, 2009, Gynecologic oncology.

Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.

A. Oza, H. Hirte, S. Lheureux, 2017 .

Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian CancerBorgoño CA, Kishi T, Scorilas A, et al (Univ of Toronto; Univ of Athens, Greece; Technical Univ of Munich) Clin Cancer Res 12:1487–1493, 2006§

J. Hurteau, 2007 .

Real-world trends of PARPi maintenance treatment uptake and progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the United States.

Jinlin Song, P. Thaker, E. Wu, 2022, Journal of Clinical Oncology.

Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer

J. Hurteau, 2007 .

Common variants at 12 p 11 , 12 q 24 , 9 p 21 , 9 q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, David Evans, 2017 .

Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective

J. Hurteau, K. Travers, Jinan Liu, 2021, Journal of managed care & specialty pharmacy.

Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2017 .